Filana Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Filana Therapeutics, Inc. (FLNA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 3.69% for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2023-02-28
- Filana Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 3.69%, a 159.86% increase from fiscal 2021.
- Filana Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2021 was 1.42%, a 82.05% increase from fiscal 2020.
- Filana Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2020 was 0.78%, a 68.80% decline from fiscal 2019.
- Filana Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2019 was 2.50%, a 13.79% decline from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|
| 2022-12-31 | 3.69% 10-K · filed 2023-02-28 |
| 2021-12-31 | 1.42% 10-K · filed 2023-02-28 |
| 2020-12-31 | 0.78% 10-K · filed 2023-02-28 |
| 2019-12-31 | 2.50% 10-K · filed 2021-03-23 |
| 2018-12-31 | 2.90% 10-K · filed 2020-03-26 |
| 2017-12-31 | 2.40% 10-K · filed 2019-03-29 |
| 2016-12-31 | 2.00% 10-K · filed 2018-02-06 |
| 2015-12-31 | 2.00% 10-K · filed 2017-03-07 |
| 2014-12-31 | 2.00% 10-K · filed 2017-03-07 |
| 2013-12-31 | 2.00% 10-K · filed 2016-03-03 |
| 2012-12-31 | 1.00% 10-K · filed 2013-02-08 |
| 2011-12-31 | 3.00% 10-K · filed 2014-02-05 |
| 2010-12-31 | 3.00% 10-K · filed 2013-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |